Baxter Presents Data at 58th ERA-EDTA Congress Indicating Theranova May Reduce Cardiovascular Events and Hospitalizations

Author's Avatar
Jun 08, 2021

Baxter International Inc. (NYSE:BAX, Financial), a global innovator in renal care, announced today new data showing expanded hemodialysis (HDx) therapy enabled by the Theranova dialyzer may reduce cardiovascular events by 35% and hospitalization rates by 18% according to a new, large, multicenter, retrospective study of Colombian dialysis patients treated with long-term HDx compared to propensity-matched patients treated with High-Flux Hemodialysis.1 The study “Effectiveness of medium cut-off versus high flux dialyzers: An inverse probability weighting cohort study,” [Abstract #MO880] was an oral presentation at the 58th European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress, June 5-8, 2021.